Clinical Trial Update: Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen [NA]

View source ↗

Summary

The ClinicalTrials.gov entry for an open-label trial of intrathecal baclofen for severe tactile defensiveness in autism has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• Baclofen (intrathecal) (baclofen)

Snippet

Sponsor: University of Missouri-Columbia | Conditions: Autism Spectrum Disorder | NA | Status: WITHDRAWN